Literature DB >> 29472056

Response to Nivolumab as Salvage Therapy in a Patient with Thymic Carcinoma.

Po-Chun Yang1, Jhe-Cyuan Guo2, Min-Shu Hsieh3, Chia-Chi Lin1, Chih-Hung Hsu4.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2018        PMID： 29472056     DOI： 10.1016/j.jtho.2017.10.022

Source DB:  PubMed          Journal:  J Thorac Oncol        ISSN： 1556-0864            Impact factor:   15.609


× No keyword cloud information.
  1 in total

1.  Pembrolizumab as a novel therapeutic option for patients with refractory thymic epithelial tumor: A case report.

Authors:  Jonathan Wong-Chong; Maureen Bernadach; Angeline Ginzac; Hugo Veyssière; Xavier Durando
Journal:  World J Clin Cases       Date:  2021-02-16       Impact factor: 1.337
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.